StockData
Acadia Pharmaceuticals Inc logo

Acadia Pharmaceuticals Inc (ACAD) stock

ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3027% below fair value
$17.83−0.49 (-2.67%)

Close on Nov 18, 2026Market cap $3.07BP/E 8.1Yield –

Acadia Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Acadia Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $86.37M, down 63.5% year over year. For fiscal 2025 it was $104.81M, down 54.6% from the year before. The highest annual figure on record is $230.79M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$104.81M-54.6%
FY2024Dec 31, 2024$230.79M–
FY2023Dec 31, 2023-$73.38M–
FY2022Dec 31, 2022-$223.60M–
FY2021Dec 31, 2021-$170.44M–
FY2020Dec 31, 2020-$286.59M–
FY2019Dec 31, 2019-$246.55M–
FY2018Dec 31, 2018-$247.44M–
FY2017Dec 31, 2017-$292.41M–
FY2016Dec 31, 2016-$272.82M–
FY2015Dec 31, 2015-$164.61M–
FY2014Dec 31, 2014-$93.23M–
FY2013Dec 31, 2013-$38.30M–
FY2012Dec 31, 2012-$20.89M–
FY2011Dec 31, 2011-$22.85M-251.4%
FY2010Dec 31, 2010$15.09M–
FY2009Dec 31, 2009-$45.47M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$37.84M+16.9%
Q1 FY2026Mar 31, 2026-$4.62M-123.9%
Q4 FY2025Dec 31, 2025$17.39M-88.7%
Q3 FY2025Sep 30, 2025$35.76M+13.0%
Q2 FY2025Jun 30, 2025$32.37M+6.4%
Q1 FY2025Mar 31, 2025$19.29M+26.8%
Q4 FY2024Dec 31, 2024$153.50M+339.3%
Q3 FY2024Sep 30, 2024$31.64M–
Q2 FY2024Jun 30, 2024$30.44M+902.2%
Q1 FY2024Mar 31, 2024$15.21M–
Q4 FY2023Dec 31, 2023$34.94M–
Q3 FY2023Sep 30, 2023-$57.78M–
Q2 FY2023Jun 30, 2023$3.04M–
Q1 FY2023Mar 31, 2023-$53.58M–
Q4 FY2022Dec 31, 2022-$46.06M–
Q3 FY2022Sep 30, 2022-$30.87M–
Q2 FY2022Jun 30, 2022-$33.65M–
Q1 FY2022Mar 31, 2022-$113.02M–
Q4 FY2021Dec 31, 2021-$44.66M–
Q3 FY2021Sep 30, 2021-$15.30M–
Q2 FY2021Jun 30, 2021-$43.71M–
Q1 FY2021Mar 31, 2021-$66.77M–
Q4 FY2020Dec 31, 2020-$67.16M–
Q3 FY2020Sep 30, 2020-$85.90M–
Q2 FY2020Jun 30, 2020-$44.01M–
Q1 FY2020Mar 31, 2020-$89.52M–
Q4 FY2019Dec 31, 2019-$56.40M–
Q3 FY2019Sep 30, 2019-$45.42M–
Q2 FY2019Jun 30, 2019-$57.09M–
Q1 FY2019Mar 31, 2019-$87.63M–
Q4 FY2018Dec 31, 2018-$67.28M–
Q3 FY2018Sep 30, 2018-$61.27M–
Q2 FY2018Jun 30, 2018-$64.08M–
Q1 FY2018Mar 31, 2018-$54.82M–
Q4 FY2017Dec 31, 2017-$70.01M–
Q3 FY2017Sep 30, 2017-$65.64M–
Q2 FY2017Jun 30, 2017-$68.04M–
Q1 FY2017Mar 31, 2017-$88.72M–
Q4 FY2016Dec 31, 2016-$78.23M–
Q3 FY2016Sep 30, 2016-$72.40M–

More Acadia Pharmaceuticals figures

See a number that looks wrong?